KRMD
KORU Medical Systems, Inc.
KRMD has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over KRMD overall, supported by stronger fundamentals and stronger modeled upside.
KRMD Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Under pressure | |
| Strong |
KRMD's revenue and balance sheet are currently healthy, and its profitability is stable, but its cash flow is under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
KRMD PE Valuation
KRMD has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 226x next year's earnings.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
KRMD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect KRMD to return to profit, with revenue growing. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
KRMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.02 | — |
| Q3 2026 | -$0.02 | +$0.07 |
| Q2 2026 | -$0.04 | +$0.06 |
| Q1 2026 | -$0.05 | +$0.07 |
| Q4 2025 | -$0.06 | +$0.07 |
| Q3 2025 | -$0.09 | +$0.17 |
| Q2 2025 | -$0.10 | +$0.16 |
| Q1 2025 | -$0.12 | +$0.17 |
| Q4 2024 | -$0.13 | +$0.17 |
KRMD is still losing money, but far less than before: $0.02 per share over the past year, against $0.30 at its worst in late 2023.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over KRMD on earnings quality, reporting a profit while its opponent remains loss making.
KRMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $11.6M | +11% |
| Q2 2026 | $12M | +18% |
| Q1 2026 | $11.8M | +22% |
| Q4 2025 | $10.9M | +23% |
| Q3 2025 | $10.4M | +27% |
| Q2 2025 | $10.2M | +21% |
| Q1 2025 | $9.6M | +18% |
| Q4 2024 | $8.8M | +23% |
KRMD's revenue has grown year over year for 11 quarters in a row: $12M last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 1.6% | +10 points |
| Q2 2026 | 5.2% | +8.3 points |
| Q1 2026 | -7.3% | +5.6 points |
| Q4 2025 | -5% | +13 points |
| Q3 2025 | -8.3% | +13 points |
| Q2 2025 | -3.1% | +11 points |
| Q1 2025 | -13% | +11 points |
| Q4 2024 | -18% | +13 points |
KRMD's operating margin was 1.6% last quarter, up 10 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over KRMD on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over KRMD on profitability, with a higher operating margin.
KRMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2M | -8973% |
| Q2 2026 | $108.2K | +$597.4K |
| Q1 2026 | -$31.5K | +$649.4K |
| Q4 2025 | $687K | -30% |
| Q3 2025 | $13K | +$2M |
| Q2 2025 | -$489.2K | -$376.2K |
| Q1 2025 | -$680.9K | -$201.1K |
| Q4 2024 | $983.2K | +9.2% |
KRMD has burned cash in most quarters: −$387,369 over the past year, against −$173,904 the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over KRMD on cash generation, producing positive trailing cash flow while its opponent burns cash.
KRMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -5.6% | -2.8M shares |
| 1 year | +1.1% | +493K shares |
| 3 years | +2.4% | +1.1M shares |
| 5 years | +5.4% | +2.4M shares |
| Available history | +20% | +7.7M shares |
KRMD has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
KRMD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -37.0x | Net Cash |
| Q3 2020 | -239.5x | Net Cash |
| Q2 2020 | -60.9x | Net Cash |
| Q1 2020 | -3.6x | Net Cash |
| Q4 2019 | -6.3x | Net Cash |
KRMD has the edge over OSCR on leverage, with a lower net debt burden relative to earnings.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
KRMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 53.0 | Neutral |
| Stochastic | 30.9 | Neutral |
KRMD's weekly RSI is 53 (neutral) and its Stochastic is 31 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
KRMD PE vs Healthcare Sector
| Metric | KRMD | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
KRMD has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
KRMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.13 | 18% above |
| 20 week MA | $3.45 | 7% above |
| 50 week MA | $4.20 | 12% below |
| 100 week MA | $3.92 | 5.9% below |
| 200 week MA | $3.39 | 8.8% above |
KRMD's trend is mixed: it's above three of its five weekly moving averages, and 8.8% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over KRMD on trend strength, trading above more of its moving averages.
KRMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $6.15 | $6.09 | -1% |
| 2021 | $6.09 | $3.25 | -47% |
| 2022 | $3.25 | $3.42 | +5.2% |
| 2023 | $3.42 | $2.46 | -28% |
| 2024 | $2.46 | $3.94 | +60% |
| 2025 | $3.94 | $6.23 | +58% |
| 2026 YTD | $6.23 | $3.69 | -41% |
KRMD has finished lower in three of the last six years. It's down 41% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over KRMD on returns for 2026, with the stronger performance.